TD Waterhouse Canada Inc. Sells 3,012 Shares of IDEXX Laboratories, Inc. $IDXX

TD Waterhouse Canada Inc. lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 34.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 5,721 shares of the company’s stock after selling 3,012 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in IDEXX Laboratories were worth $3,076,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the second quarter valued at about $25,000. SHP Wealth Management acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $26,000. Elevation Wealth Partners LLC raised its holdings in shares of IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after acquiring an additional 32 shares during the last quarter. Virtus Advisers LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at about $26,000. Finally, WealthCollab LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at about $30,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on IDXX shares. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, August 27th. UBS Group raised their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays decreased their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $535.38 on Tuesday. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98. The firm has a 50-day moving average price of $558.25 and a two-hundred day moving average price of $569.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The firm has a market cap of $42.18 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.86 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.